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Objectives. The objectives of the study were (i) to evaluate the eﬃcacy of combination drugs, such as artesunate + sulphadoxine-
pyrimethamine (AS+SP) and amodiaquine + sulphadoxine-pyripethamine (AQ+SP) in treatment of uncomplicated falciparum
malaria (ii) to diﬀerentiate recrudescence from reinfection by analysing msp-1 and msp-2 genes of Plasmodium falciparum in
treatment failure cases. Methods. We carried out an in vivo study in the year 2005 in 206 children between 6 to 59 months age
groups. Of the 206, 120 received AQ+SP, and 86 received AS+SP. A clinical and parasitological followup during 14 days was
undertaken. Finger-prick blood sample from each patient was taken on Whatman ﬁlter paper (no. 3) on days 0, 7, 14 and also the
day when the parasite and symptoms reappeared for PCR analysis. Results. Late treatment failure was observed in 3.5% (4/114)
with AQ+SP, and 2.5% (2/79) with AS+SP. The success rate was 96.5% with AQ+SP and 97.5% with AS+SP. No deaths and
severe reactions were recorded. Out of the 6 treatment failure cases, one was reinfection as observed by PCR analysis of msp-1
and msp-2 genes on day 14. Discussion. Both the combinations found to be eﬃcacious and safe and could be used as a ﬁrst-line
treatment for uncomplicated falciparum malaria in Equatorial Guinea.
Copyright © 2009 Pilar Charle et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Background
Malaria is the major cause of morbidity and mortality in
children under ﬁve years in Sub-Saharan Africa [1]. In
areas of stable malaria transmission, like Equatorial Guinea,
25–40% of the patients in clinics and 20–50% of hospital
admissions are due to malaria. The falciparum malaria is the
cause of at least 20% of death in fewer than ﬁve years old
children [1].
In Sub-Saharan Africa, the mortality in children under
ﬁve years old during the period between 1990 and 1998
was doubled compared with the period from 1982 to 1989.
One of the most important reasons of this increase in the
mortality rates is the spread of antimalarial drug resistance
in Africa [2].
The prevalence of malaria infection in children less than
ﬁve years is 22% and 48% in Malabo (Island Region) and
in Bata (Continental Region). The more frequent species2 Journal of Tropical Medicine
in Malabo are Plasmodium falciparum (92%), P. malariae
(3%), P. ovale (1%), and mixed infection (4%); in Bata are
Plasmodium falciparum (97%), P. malariae (2%), and mix
infection (1%) (unpublished data).
A lot of African countries have the necessity of review
its malaria treatment. In Equatorial Guinea, as per the
National Malaria Program, chloroquine (CQ) is the ﬁrst
line of treatment, whereas quinine is for treatment of severe
malaria. Due to the initiative of Medical Care International
Development (MCDI), The Equatorial Guinea Ministry of
Health has started to use the combination of AS + SP as a
ﬁrst line treatment of uncomplicated falciparum malaria in
children and pregnant women since 2004 in Bioko Island.
In diﬀerent in vivo studies carried out in Equatorial
Guinea (Bioko Island) by the Institute of Health Carlos III
(Madrid,Spain),incollaborationwiththeMinistryofHealth
of this country from 1992 to 1999, it was concluded that
resistance to cloroquine (CQ) was over 40% in children
under ﬁve, and resistance to sulphadoxine-pyrimethamine
(SP) was around 25% in the same age group. In the
continental area of the country, studies undertaken during
2001 gave the same results as in the island [3].
During the years 2002 and 2003, the sensitivity of Plas-
modium falciparum to AS + SP combination was evaluated
in Equatorial Guinea (unpublished study), and an adequate
clinical response of 95% was achieved.
As a result of the problem of drug resistance developed
in P. falciparum, the Word Health Organization (WHO) rec-
ommended to improve access of population to a quick and
eﬃcacy treatment to decrease the burden of malaria [4]. The
current recommendation is the use of a combination therapy
followingtheexperienceoftreatmentsinotherdiseases,such
as tuberculosis, leprosy, and HIV infection. A combination
therapy would be helpful in simultaneous use of two or
morebloodschizontocidaldrugswithindependentmodesof
action and diﬀerent biochemical targets in the parasite [5].
Present study was undertaken jointly with the Malaria
National Control Program for evaluation of AS + SP and
AQ + SP combinations in treatment of uncomplicated
falciparum malaria. AQ + SP combination is presently
recommended by the WHO, if the eﬃcacy is acceptable [6].
It is less expensive than a combination with artesunate and
can be used as a ﬁrst line of treatment keeping in view the
economic resources of the country rather than introducing
directly a combination with artesunate. The second one AS
+ SP is being used in the Island, and its eﬃcacy needs to be
monitored for its further use in the Malaria National Control
Program.
For any in vivo study, it is necessary to diﬀerentiate
recrudescence or reinfection, when the country is having
high incidence of malaria and with a high transmission rate.
For this reason, polymorphic markers as msp-1 and msp-2 or
microsatellite markers are useful for this purpose [7].
In this study, we evaluated the eﬃcacy of the AS +
SP and AQ + SP combinations as a ﬁrst-line treatment
for uncomplicated malaria in Equatorial Guinea, and the
outcome of infection and treatment was determined by
molecular analysis to present a real scenario on use of these
two combinations.
2.MaterialandMethods
2.1.AreaandStudyPopulation. EquatorialGuineaissituated
in Central Africa, in the Guinea Gulf. It is divided in
two regions, the continental area, called Rio Muni between
Cameroon and Gabon, and the Island Region (Bioko,
Annob´ on and Corisco Valley). Bioko, the biggest island, is
placed 40km from Cameroon coast. Population estimation
is around 484000 habitants in an area of 28051km
2 between
both regions [8]. Around 75% of the population lives in the
Continental Region.
Malabo is the capital of the country and is placed in the
IslandofBioko.Thereisatropicalclimatewitharainyseason
from May to October and a dry period from December
to March. It is a mesoendemic transmission area with a
Plasmodium index of 21.7% in 2005 [9]. Bata is the most
important city in the continental region and has also a trop-
ical climate with two dry seasons (December–March, June–
September)andtworainyseasons(March–June,September–
December) alternate. It is a mesohyperendemic area with
a Plasmodium index between 41% and 75% in children
under ﬁve years old. (Unpublished study from a National
Prevalence Survey 2006, Ministry of Health and Instituto de
Salud Carlos III.)
In December 2005, an in vivo study was carried out in
the two Regional Hospitals of Malabo and Bata. The study
followed the WHO methodology [10]. The cases that were
included in the assessment came from the paediatric external
consultation.
It was a two-armed prospective evaluation of the clinical
and parasitological responses to diﬀerent antimalarial com-
binations, as AS + SP and AQ + SP. The minimal sample size
was diﬀerent depending on the combinations. In order to
have a conﬁdence level of 95% and a precision of 10% and as
the proportion of treatment failure with AS + SP was already
known, a minimum of 50 patients had to be included. With
AQ + SP, there was no evidence of treatment failure, so the
minimum sample size had to be 96 for having a precision of
10% with a conﬁdence level of 95% [10].
2.2. Procedures, Treatment and Followup. All the children
were medically screened. The inclusion criteria were age
between 6 to 59 months, no signs of severe malnutrition,
a slide conﬁrmed monoespeciﬁc infection of P. falciparum,
parasite density between 2000 and 200000 asexual para-
sites/microlitre, axillary temperature >37.5◦C, easy access to
the hospital, absence of history of hypersensitivity reactions
to any of the drugs being evaluated and informed consent
provided by parents or caregivers. Any danger signs of severe
malaria such as inability to drink or breastfeed, vomiting,
recent history of convulsions, lethargy, and inability to sit or
stand up were considered as exclusion criteria.
Allthechildrenwererandomlyassignedtoonetherapeu-
tic arm. They were evaluated clinically and parasitologically
during 14 days; treatment was given during the ﬁrst three
days under direct observation.
A record form, which included: age, sex, address, name
of the caregiver, contact telephone (if available), was main-
tained.Duringthefollowup,parameterssuchastemperatureJournal of Tropical Medicine 3
(during the six days), doses of drug (days 0, 1, and 2),
p a r a s i t a e m i a( d a y s0 ,1 ,2 ,3 ,7 ,a n d1 4o rw h a t e v e rd a y
that children was bringing to the hospital), haematocrit
(days 0 and 14) and ﬁlter paper (days 0, 14, or any day
in case of treatment failure for analysis of the molecular
markers) were recorded. Finger prick blood samples that
were collected in Whatman paper and in a thick-and-
thin smear stained with Giemsa for microscopy exam were
undertaken.
Parasitaemiawasquantiﬁedbyastandardapproximation
method, that is, number of asexual parasites seen per 200
white blood cells in a high-power examination of a thick
blood ﬁlm. A positive smear was deﬁned as the presence
of at least one asexual parasite seen after examining 100
thick smear ﬁelds. Quality control of blood smears was done
by rereading 10% of slides selected randomly. Discordant
results were subjected to a third microscopist. Haematocrit
was measured by microhaematocrit centrifugation on days 0
and 14.
Drugs used were amodiaquine 150mg (Holden Medical,
set. 04L02. Expired 11/2007), artesunate 50mg (Action
medeor. Lot. 055585. Expired 11/2008), sulphadoxine
500mg + pyrimethamine 25mg (IDA. Lot. SPF-200 Expired
11/2008), quinine 200mg (Holden Medical. Lot MFF 371/05
A 01. Expired 12/2007).
Amodiaquine was given as 10mg/kg of body weight per
day for three days. Artesunate given as 4mg/kg of body
weight per day for three days and sulphadoxine-pyrim-
ethamine given as sulphadoxine 500mg + pyrimethamine
25mg/kg of body weight in a single dose for the ﬁrst day. In
case of treatment failure, quinine at 10mg/kg of body weight
every 8 hours for seven days was administered.
2.3. Deﬁnition of Treatment Failure. The eﬃcacy outcome
wasmeasuredbasedonparasitologicalclearanceratesonday
14. The criteria to determine the treatment failure were the
following: early treatment failure (ETF) was considered if
development of severe malaria or danger signs during days
1, 2, or 3 in presence of parasitaemia, or parasitaemia on day
2 is higher than day 0 irrespective of axillary temperature, or
parasitaemia on day 3 with axillary temperature >37.5◦C, or
parasitaemia on day 3 more than 25% of day 0.
Late clinical failure (LCF) was considered by develop-
ment of severe malaria or danger signs after day 3 with par-
asitaemia without previous criteria of ETF, or parasitaemia
and temperature >37.5◦Co na n yd a yb e t w e e n4a n d1 4
without previous criteria of ETF. Late parasitological failure
(LPF) was determined based on the presence of parasitaemia
b e t w e e nd a y s7a n d1 4w i t ht e m p e r a t u r e>37.5◦C, without
previous criteria of ETF or LCF. Adequate clinical and
parasitological response was determined (ACPR) by the
absence of parasitaemia on day 14, irrespective of axillary
temperature, without meeting the criteria of ETF, LCF, and
LPF.
Some of the cases were considered as Withdrawal, when
caregivers of children decided not to continue with the study
despite all eﬀorts and lost to follow up; children could not be
found at hospital, in the community, or in the study area.
2.4. DNA Extraction and Molecular Study. We extracted
DNA from individual blood sample collected on Whatman
ﬁ l t e rp a p e r .W ec u tac i r c l eo fp a p e r( 4 0m mØ )w i t hb l o o d ,
and DNA was extracted by Phenol/Chloroform method.
This DNA was used for the diﬀerent molecular assays: (a)
semi-nested-Multiplex PCR for the diagnosis of Malaria to
conﬁrm the Plasmodium species (b) study of the msp-1 and
msp-2 genes of P. falciparum through nested-PCR [7]. In
order to distinguish recrudescence from reinfection cases,
we studied the three diﬀerent allelic families of msp-1g e n e :
Mad20, RO33 and K1, and msp-2 gene. Recrudescence was
deﬁned as the same population of parasites appeared on day
7 or day 14 as in day 0. Reinfection was deﬁned as a new
population of parasites detected on day 14 compared to day
0. After the PCR, we analysed the result in the Bioanalyzer
2100 expert (Agilent Technologies), this method has a
very high resolution and we can distinguish ampliﬁcation
fragments with a little diﬀerence in the basepairs.
2.5. Statistical Analysis. Baseline characteristics, means, and
percentageswerecomparedin study subjectsofbothareasby
Student t-test and by chi-square test respectively. The non-
parametric alternative for t-test and Mann-Whitney test was
used to compare the baseline parasite density. Therapeutic
eﬃcacy was calculated by dividing the number of ACPR
cases by the number of patients evaluated on 14th day.
The 95% conﬁdence intervals for drug eﬃcacy were also
calculated. Log-rank test for equality of survivor functions
was calculated in order to compare time to parasitological
clearance.
3. Results
Between August and December 2005, 206 children were
randomised from the external consultation of Malabo and
Bata Regional Hospitals in order to evaluate the eﬃcacy
of two antimalarial combinations: AQ + SP and AS + SP.
Baseline characteristics of children are shown in Table 1.A s
expected, no diﬀerences were found between groups, except
in the weight.
The enrolled children were given one of the two combi-
nations in a random way: 120 were treated with AQ + SP and
86receivedAS+SP.Intheﬁrstgroup95%(114/120)ﬁnished
the study and 91.9% (79/86) in the second group. The trial
proﬁle appears in the Figure 1.
There were 13 children who lost to follow up in AQ + SP
group. The percentage of lost to follow up was 5% (6/120)
and in the AS + SP arm was 8.1% (7/86). In general children
who lost to follow up were fewer (6.3%; 13/206) than 10% of
the children as per WHO recommendations.
With AQ + SP, 4 cases of LPF were registered and the
proportion of treatment failure was 3.5% (4/114). The ACPR
was 96.5% (conﬁdence interval 95%: [91.3%–99%]). With
AS + SP, 2 cases of LPF 2.5% (2/79) were registered, the
cure rate was 97.5% (C.I. 95%: [91.2%–99.7%]). All of the
failure cases received rescue treatment with oral quinine and
cured(seeTable 2).Afterthemolecularcorrection,theACPR
changed from 96.5% to 97.3% with AQ + SP combination.4 Journal of Tropical Medicine
Table 1: Baseline characteristics.
Amodiaquine + sulphadoxine-pyrimethamine Artesunate + sulphadoxine-pyrimethamine
Sex
Male (%) 62 53
Age in months (mean ± sd) 28.2 (15) 26.7 (15)
Weight in Kg (mean ±sd)
∗ 12.7 (4) 11.7 (3)
Temperature in oC (mean ± sd) 38.2 (1) 38.3 (1)
Parasites/microlitre (median/IR) 23,882 (9,360–30,480) 24,978 (20,040–31,640)
Haematocrit 30 (4) 31 (4)
∗P<. 05;$P<. 01; sd (standard deviation); IR (Interquartile rank).
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Figure 1: Trial proﬁle.
Table 2: Treatment outcomes observed in the patients of Bata and Malabo Hospitals. The results appear in the diﬀerent groups with two
combination drugs.
Treatment Total AQPR ETF LPF LCF
No %N o %N o %N o %
amodiaquine + sulphadoxine-pyrimethamine 114 110 96.5 0 0.0 4 3.5 0 0.0
artesunate + sulphadoxine-pyrimethamine 79 77 97.5 0 0.0 2 2.5 0 0.0Journal of Tropical Medicine 5
Table 3: Number of alleles of msp-1 allelic family, and the alleles detected in msp-2. In case of isolate 293, new populations appeared on day
14, one for RO33 (150bp) and two for msp-2 (600bp and 700bp).
msp-1
Locality Treatment K1 MAD20 RO33 msp-2
36D0 Bata AQ/SP 135/155/225 0 0 570/755
36D14 155 0 0
11D0 Bata AQ/SP 190/205/290 150 500/530/590
11D14 500
102D0 Bata AQ/SP 210/250/265 195/210/240 150 535/590
102D14 150
75D0 Bata AS/SP 160/220/250 150 575/670
75D14 150
29D0 Malabo AQ/SP 135/225 490/525/665
29D14 150 600 / 700
2D0 Malabo AS/SP 210/250/265 195/210/240 150 535/590
2D14 ∗ ∗∗∗
Both combinations were well tolerated, no deaths were
notiﬁed and no severe reactions were recorded, except 3
patients (2.5%) had complaints of itching in AQ + SP treat-
ment group, they were given antihistamine. Four patients
(3.3%)inAQ+SPand1patient(1.2%)inAS+SPtreatment
groups vomited, which could not be conﬁrmed whether this
was the consequence of malaria or the treatment eﬀect.
The parasite clearance (Figure 2) was faster in the group
who received the combination with artesunate (log-rank test
P<. 001). In AS + SP treatment group, 77.2% (61/79) and
in AQ + SP treatment group, 94.7% (108/114) presented
parasitemia on day 1. On day 2, 3.8% (3/79) of AS + SP
and 55.3% (63/114) of AQ + SP treatment groups were
parasitemic. By day 3, all of them were negative.
Baseline gametocyte carriage was less than 5% in both
arms. After receiving treatment, gametocyte density was
found to be higher in AS + SP patients than AQ + SP.
With the ﬁrst combination, by day 2, 12% of children had
gametocytes on the thick ﬁlm, compared with the 7.5% with
AQ + SP. By day 3, the 7.8% with AS + SP and the 6% with
AQ + SP had gametocytes. By day 14, gametocytemia was
under 2% with both the combinations.
Haematocrit at enrolment showed that 37% of the
children had moderate anaemia with haematocrit 24–29,
49% had mild anaemia with haematocrit 30–34, and 14%
were nonanaemic. After treatment the moderate anaemia
decreased from 37% to 23%, and nonanaemic cases
increased from 14% to 22%.
Molecularcorrectionwasdonetodistinguishrecrudescent
from reinfection in 6 treatment failure cases: 4 cases from
Bata, 3 in the AQ + SP combination, and 1 in the AS + SP,
and 2 in Malabo with two combinations (AQ + SP and AS
+S P ) .Table 3 shows the number of alleles of msp-1 allelic
family, and msp-2 detected in the six treatment failure cases.
We could conﬁrm the resistant cases from Bata by molecular
analysis; because the parasite genotypes detected by PCR on
day 14 were similar with those on day 0. However, in the AQ
+ SP treatment failure cases from Malabo, one of them was
reinfection because a diﬀerent set of genotypes appeared on
day 14 as shown in Table 3.
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Figure 2: Proportion of parasites clearance with the two combina-
tions.
4. Discussion
There is a need to give a thought about any monotherapy
as a ﬁrst-line treatment in case of patients report with
uncomplicated falciparum malaria. Keeping this in view,
present study was undertaken on the drug sensitivity of two
diﬀerent therapeutics combinations. This study would be
helpful in National Malaria Control Program of Equatorial
Guinea to introduce a new combination therapy for malaria
treatment.
Two combinations were assessed, the combinations AS
+ SP, where the AS is an eﬃcacious drug and reduces the
parasitaemiafasterthanothers,andthesecondcombination,
AQ + SP, is also an eﬀective combination but with the risk to
developresistantinduecourseoftime,butmoreaccessibleto
the population when compared with artemisinin derivatives.
T h es t u d yd e m o n s t r a t e dt h a tb o t hc o m b i n a t i o n sa r e
safe and eﬃcacious for the treatment of nonsevere fal-
ciparum malaria in Equatorial Guinea. These results are
similar to other studies made in diﬀerent African’s areas. A
study carried out in Tanzania in an area of high malaria6 Journal of Tropical Medicine
transmission compared the eﬃcacy and safety of AQ and SP
in monotherapy and AQ + SP as a combination. The study
demonstrated that AQ + SP combination was safe, and the
combination of the two drugs had higher eﬃcacy (96.2%)
than monotherapy [11]. In a similar study carried out in
Gambian children, concluded that AS + SP combination was
safe and the eﬃcacy was 98.4% [12]. A study carried out
in Guinea showed an eﬃcacy of 99% with this combination
[13]. These results are similar to those of the present study
with cure rates of 97.5% (77/79) in AS + SP combination
and 97.3% (111/114) in AQ + SP. The situation in Equatorial
Guinea is similar with other African countries. The cure-
rates with the two combination drugs, AQ + SP and AS +
SP, are over the 95%, which is the limit that WHO suggested
for a combination to be used as a ﬁrst line of treatment [6].
In general terms, drugs were well tolerated, with a low
percentage of adverse eﬀects. In the group that received AQ
+ SP, a small number of children required retreatment after
vomiting after treatment. Severe reactions with amodiaquine
as neutropenia have been described also in other publica-
tions. In one study, it was shown that the risk was associated
with amodiaquine used as a weekly prophylaxis, not like a
treatment [14]. In a study carried out in Madagascar, using
combination of AQ + SP like our work, no severe reaction
was described using AQ in a 3-day treatment schedule
[15].
Clearance of parasites was faster in case of combination
with artemisinin derivatives, due to the mode of action of
artemisine, which reduces parasitaemia by a factor of 10
in each cycle. In Uganda, was described the diﬀerence in
parasitemia clearance using a combination with and without
artemisinin derivatives. By day two, in the ﬁrst case just 3%
werepositivecomparedtothesecondgroup,where48%were
positive [16]. These results coincide with our study, where by
daytwo,3.8%wereparasitaemiccomparedwiththe55.3%of
childrenwhoreceivedAQ+SPonthesameday.Duetofaster
parasite clearance, clinical improvement and disappearance
of symptoms were faster in children treated with AS + SP.
Because of this rapid eﬀect, use of artemisinin derivatives in
a combination would be appropriate in terms of decreasing
thepossibledevelopmentofparasiteresistancetothedrugby
rapid clearance thus they are not in contact with the drug for
al o n gt i m e[ 17].
Contrarytootherstudies,wehavenotseenanydiﬀerence
in gametocytes carriage. From this study, we could not say
that using of artemisinin-based combination therapies may
reﬂect in decrease of malaria transmission in the area. One
study in Tanzania, where diﬀerent drugs in monotherapy
and combinations were compared, demonstrated that AQ +
SP gametocytes on day 14 were 25.7% in children, which
was double than using the combination with AS, where just
11.9% of children had gametocytes [18].
Both the combinations had SP. It is necessary to assess
other therapies without this drug due to the following
reasons. First, SP is the only safe drug actually to be used
as Intermittent Preventive Treatment for pregnant women.
Following WHO recommendations, we need to protect the
future development of resistance to this drug. And the
second reason is that SP has a resistance around 18% in
monotherapy (unpublished data, 2002). Drugs that have
been used for a long time as monotherapy and have already
demonstratedresistancehavetherisktodevelopresistancein
combination in due course of time.
From the results of this study, we may suggest that
in all in vivo studies a molecular assay for discriminating
recrudescence from reinfection should be done. The molec-
ularcorrectionistheonlymethodthatallowsustogiveareal
dataaboutthelevelofresistancedetectedinanendemicarea.
This way, it is possible to analyse diﬀerent markers like msp-
1a n dmsp-2 genes of P. falciparum, or other polymorphic
m a r k e r sa sm i c r o s a t e l l i t e s[ 19].
We need to continue the epidemiological surveillance
and monitoring resistance in order to give enough informa-
tion to the National Malaria Program of Equatorial Guinea
for revising malaria treatment policy in the country. This
should be done as per the recommendation of WHO before
the drug resistance reaches at levels not allowed to be used.
The conclusions of this study are that both the com-
binations are safe and eﬃcacious for their use as a ﬁrst-
line treatment in case of nonsevere falciparum malaria. To
choose one of them will depend on economic resources of
EquatorialGuineainthemomenttochangeMalariaPolicyof
the country; the molecular correction gives complementary
information to strengthen the ﬁndings of in vivo studies
carried out in areas with a high level of transmission.
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